Related Experiment Video
Updated: May 17, 2026
09:40
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Could circulating miRNAs contribute to cancer therapy?
Geng Chen1, Juan Wang, Qinghua Cui
1Institute of Systems Biomedicine, Peking University, Beijing, 100191, China.
Trends in Molecular Medicine
|November 3, 2012
Summary
Circulating microRNAs (miRNAs) show promise in cancer therapy. Tumor-suppressing miRNAs increase while oncogenic miRNAs decrease in cancer patients, potentially enhancing immune defense against cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Immunology
Background:
- Circulating microRNAs (miRNAs) are small non-coding RNAs found in bodily fluids.
- Their precise roles in disease, particularly cancer, are under investigation.
- Emerging evidence suggests miRNAs are involved in cancer development and progression.
Purpose of the Study:
- To explore the potential of circulating miRNAs as therapeutic agents in cancer.
- To understand the relationship between circulating miRNA levels and cancer status.
- To investigate the link between circulating miRNAs and the immune system's response to cancer.
Main Methods:
- Analysis of circulating miRNA expression profiles in cancer patients.
- Correlation studies between miRNA levels and tumor-suppressing or oncogenic activity.
- Investigation of the association between circulating miRNAs and immune response markers.
Main Results:
- In cancer patients, levels of tumor-suppressing circulating miRNAs were elevated.
- Conversely, levels of oncogenic circulating miRNAs were decreased in cancer patients.
- A significant correlation was observed between circulating miRNA populations and immune response.
Conclusions:
- Circulating miRNAs may play a role in modulating the immune system's anticancer activity.
- These findings suggest circulating miRNAs could represent a novel therapeutic strategy for cancer treatment.
- Further research is warranted to elucidate the mechanisms and therapeutic potential of circulating miRNAs in oncology.
More Related Videos
Related Concept Videos
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...